Publication

EHA •
15 June, 2025 •
•

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Aaron T Gerds, Lucia Masarova, Nicole M Engel-Nitz, Michael Marrone, Jefferey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lindsay AM Rein

Available materials

Poster

Publication

EHA •
15 June, 2025 •
•

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Doug Tremblay, Abiola Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju, James Rossetti

Available materials

Poster

Symposium

EHA •
14 June, 2025 •
•

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Monica Carpenedo, María Luisa Lozano, Waleed Ghanima

Available materials

Slides Video

Publication

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight​

Putting on your VEXAS goggles: Seeing what’s in plain sight